Preclinical Studies on Intestinal Administration of Antisense Oligonucleotides as a Model for Oral Delivery for Treatment of Duchenne Muscular Dystrophy

Preclinical Studies on Intestinal Administration of Antisense Oligonucleotides as a Model for Oral Delivery for Treatment of Duchenne Muscular Dystrophy

Antisense oligonucleotides (AONs) used to reframe dystrophin mRNA transcripts for Duchenne muscular dystrophy (DMD) patients are tested in clinical trials. Here, AONs are administered subcutaneously and intravenously, while the less invasive oral route would be preferred. Oral delivery of encapsulat...

Full description

Bibliographic Details
Main Authors: Maaike van Putten, Courtney Young, Sjoerd van den Berg, Amanda Pronk, Margriet Hulsker, Tatyana G Karnaoukh, Rick Vermue, Ko Willems van Dijk, Sjef de Kimpe, Annemieke Aartsma-Rus
Format: Article
Language:English
Published: Elsevier 2014-01-01
Series:Molecular Therapy: Nucleic Acids
Subjects:
antisense oligonucleotides
bioavailability
Duchenne muscular dystrophy
dystrophin
oral administration
Online Access:http://www.sciencedirect.com/science/article/pii/S216225311630350X

Internet

http://www.sciencedirect.com/science/article/pii/S216225311630350X

Similar Items